Riskpilot← Back to searchSign inGet full accessMedQuick AB
ABActiveOrg 5590242292Klows Väg 2Technical testing and analysis · NACE 7120Est. 20151 employees
Revenue 2025
SEK 1,7M
+710% vs 2024
EBITDA margin
85.2%
+437% vs 2024
Equity ratio
89.1%
Financial strength
Net profit 2025
SEK 1,2M
+598% vs 2024
| Revenue | SEK 1,7M | +710% |
| EBITDA | SEK 1,5M | +437% |
| Net profit | SEK 1,2M | +598% |
| Total assets | SEK 1,4M | +699% |
| Equity | SEK 1,3M | +2281% |
| Employees | 1 | — |
Legal name
MedQuick AB
Org number
5590242292
Legal form
Aktiebolag
NACE code
7120 · Technical testing and analysis
Founded
26 augusti 2015
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Konsultverksamhet inom kvalitet och kvalitetskontroll för medicintekniska produkter och tjänster.
Address
Klows Väg 2
Email
annfranz64@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 33 | 85 | 2 629 | 216 | 1 745 |
| Staff expenses | — | — | −1 476 | −627 | −222 |
| EBITDA | 18 | −26 | 1 052 | −441 | 1 486 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 18 | −26 | 1 052 | −441 | 1 486 |
| Net financials | — | — | 0 | 10 | −3 |
| Profit before tax | 18 | −26 | 867 | −246 | 1 483 |
| Tax | −0 | −0 | −117 | — | −256 |
| Net profit | 18 | −26 | 750 | −246 | 1 227 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 280 | 128 | 1 422 | 180 | 1 437 |
| Equity | 115 | 89 | 800 | 54 | 1 280 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 165 | 39 | 437 | 126 | 156 |
| Total debt | 165 | 39 | 437 | 126 | 156 |
EBITDA margin
85.2%
This company
15.8%
Market median
+439% vs market
20212025
Equity ratio
89.1%
This company
38.2%
Market median
+133% vs market
20212025
Return on equity
95.8%
This company
18.4%
Market median
+421% vs market
20212025
Net profit margin
70.3%
This company
8.1%
Market median
+768% vs market
20212025
Asset turnover
1.21×
This company
1.12×
Market median
+8% vs market
20212025
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MedQuick AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anthon Tobias Daniel Franz | Deputy Board Member | 0 companies |
| Ann Gurli Franz | Board of Directors | 0 companies |